✦ LIBER ✦

812-4 Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study

✍ Scribed by Jorge R Kizer; Aud Hoieggen; Michael H Alderman; Sverre E Kjeldsen; Bjorn Dahlof; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Marku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Jonathan M Edelman; Steven M Snapinn; Richard B Devereux

Book ID: 119549625
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 118 KB
Volume: 43
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(04)92011-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Body Build and Risk of Cardiovascular Ev

Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy. The LIFE (Losartan Intervention For Endpoint reduction in hypertension) Study

✍ G. de Simone; K. Wachtell; V. Palmieri 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Cost-effectiveness of losartan-based the

Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

✍ McInnes, G; Burke, T A; Carides, G 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

Effects of losartan on cardiovascular mo

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A losartan intervention for endpoint reduction (LIFE) study

✍ S.E. Kjeldsen; B. Dahlor; R.B. Devereux 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Prognostic importance of hemoglobin in h

Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study

✍ Michael Hecht Olsen; Kristian Wachtell; Gareth Beevers; Björn Dahlöf; Richard B. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 314 KB

PCV52 LOSARTAN-BASED VERSUS ATENOLOL-BAS

PCV52 LOSARTAN-BASED VERSUS ATENOLOL-BASED THERAPY IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: AN ECONOMIC EVALUATION OF THE LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION IN HYPERTENSION (LIFE) STUDY FOR GERMANY

✍ KJ Krobot; GW Carides; A Wagner; TA Burke 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

The interaction between aspirin and losa

The interaction between aspirin and losartan on cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. A losartan intervention for endpoint reduction (LIFE) substudy

✍ Eigil Fossum; Sverre E. Kjeldsen; Björn Dahlöf; Richard B. Devereux; Stevo Juliu 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 74 KB